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Abstract
Background: Giant cell tumor of the bone (GCT) has high local recurrence rates and the prognosis is hard to
predict. We therefore retrospectively analyzed clinical outcome and recurrences of 51 GCT cases focusing on the
effects of adjuvant local use of hydrogen peroxide.
Methods: The series enclosed 51 advanced GCT cases of the upper and lower extremities (n = 27 Campanacci
grade III; n = 24 grade II; n = 39 surgery at our institution, n = 12 elsewhere). Mean follow-up was 88.3 (± 62.0)
months. Surgical details, histology, metastases, recurrences, and interview-based data on satisfaction and function
including the Musculoskeletal Tumor Society (MSTS) score were evaluated. It was investigated whether hydrogen
peroxide was additionally used or not to clean the tumor cavity after curettage as we hypothesized influence on
recurrences. To analyze the underlying mechanisms, GCT-derived stromal cell lines were cultured in vitro and tested
for cell viability and apoptosis after treatment with hydrogen peroxide. Statistical analysis was performed with
Student’s t tests, analysis of variance (ANOVA) with post hoc testing, Mann-Whitney U tests, chi-square tests, Kaplan-
Meier analysis, and multivariate Cox regression analysis.
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Results: The whole series had 21 recurrences (41%). Eleven recurrences were found (28%) after surgery at our
institution. Kaplan-Meier analysis of cumulative recurrence-free survival revealed at 2 years follow-up 69% (72%, only
our institution) and at 10 years follow-up 54% (68%, only our institution). Intralesional resection was performed by
vigorous curettage, burring, and defect filling with either polymethylmethacrylate bone cement (n = 45) or
cancellous bone from the iliac crest (n = 6). Univariate chi-square analysis showed significantly lower recurrence rate
after bone cement filling (2.3-fold, p = 0.024). Cleaning of the lesion cavity with hydrogen peroxide significantly
reduced recurrence rate (whole collective 2.9-fold, p = 0.004; our institution 2.8-fold, p = 0.04) and significantly
increased cumulative recurrence-free survival rate (whole collective at 10 years follow-up 74% versus 31%, p = 0.002;
our institution 79% versus 48%, p = 0.02) compared to cases without hydrogen peroxide treatment. In multivariate
analysis, significant risk factors for recurrence were pathological fracture (hazard ratio 3.7; p = 0.04), high mitosis rate
(hazard ratio 15.6; p = 0.01), and lack of hydrogen peroxide use (hazard ratio 6.0; p = 0.02). In vitro cell culture
analyses found apoptotic nature of hydrogen peroxide induced GCT cell death.
Conclusions: The present series proved for the first time that additional cleaning of the tumor cavity with
hydrogen peroxide before defect filling significantly reduced recurrence rate and significantly increased recurrence-
free survival in advanced but intralesionally treated GCT cases.
Keywords: Giant cell tumor, Intralesional resection, Curettage, Bone cement, Hydrogen peroxide,
Background
Giant cell tumor of the bone (GCT) is a challenging ortho-
pedic disease representing 10–15% of all benign and 4–5%
of all primary bone tumors [1]. GCT has unpredictable bio-
logical behavior with locally destructive growth, frequent
local recurrences, multifaceted histological appearance, and
potential of pulmonary metastases [2–4]. Sixty to eighty
percent of all GCTare found in the third and fourth decade
of life. Women have a higher risk than men [5]. At the time
of initial diagnosis, pathological fracture with clinical symp-
toms of instability is often already evident [2, 6]. Systemic
therapy with denosumab has been introduced as a new en-
couraging tool to limit activity and growth of GCT but has
also been discussed controversially because of unclear ben-
efits and risks [4, 7–9]. Surgical treatment remains the gold
standard but new surgical treatment strategies have not
been established for a long time, and the literature reports
highly heterogeneous study results with inconsistent data
[5, 7–13]. Avoiding local recurrence and achieving the best
functional outcome remains a hard challenge. Despite re-
currence rates up to 65%, intralesional resection with joint
preservation and vigorous curettage is most often preferred
due to less morbidity compared to extralesional resection
[3, 5, 14–16]. Most authors prefer polymethylmethacrylate
(PMMA) bone cement filling after curettage instead of can-
cellous bone, but evidence is inconsistent [13–21].
Cell-toxic local adjuncts such as phenol can reduce the risk
for recurrence [22]. Multiple other local adjuvants have
been described such as liquid nitrogen, alcohol, iodine,
cyclophosphamide, and especially hydrogen peroxide, but
due to their heterogeneous use, the effectiveness on recur-
rence rates and recurrence-free survival has never
been proven for one of these individual substances, so
far [5, 18, 22, 23].
The aim of the study was to retrospectively analyze re-
currence rates, cumulative recurrence-free survival rates,
metastases, complications, and functionality and satisfac-
tion after surgical treatment of progressed but intrale-
sionally treated GCT cases. As a novelty of this study,
we focused on the additional effect of adjuvant local
hydrogen peroxide treatment. For the first time, the
present study presents proof of principle in a clinically
relevant in vitro analysis of hydrogen peroxide effects on
GCT cells together with retrospective clinical data of
progressed GCT cases either treated with hydrogen per-
oxide or not.
Methods
Retrospective analysis of surgical outcome
We included all benign GCT cases of the upper and
lower extremities followed in our musculoskeletal oncol-
ogy outpatient clinic from 2000 to 2017 (level I bone
and soft tissue tumor center and orthopedic and trauma
surgery university hospital). Approval was given by our
local ethical committee. Multilocular GCT, lesions of the
pelvis and spine, cases with follow-up less than 6
months, and cases without sufficient information regard-
ing H2O2 application in the surgical reports were ex-
cluded. The final sample size was 51 patients, including
39 patients with first surgical treatment at our institu-
tion and 12 patients with first surgery elsewhere. Mean
follow-up was 88.3 (± 62.0) months. Minimal follow-up
was 7 months. Mean patient age was 38.7 (± 13.3) years,
n = 26 were male, and n = 25 were female. No patient
was lost to follow-up.
Diagnosis was verified by open incision biopsy. Surgi-
cal strategy was intralesional resection with aggressive
curettage. After curettage, the cavity was most often
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filled with polymethylmethacrylate bone cement (n = 45;
Fig. 1; Palacos® R+G; Heraeus Medical, Hanau,
Germany) and less frequently with cancellous bone from
the iliac crest (n = 6). The upper extremity was affected
in n = 9 and the lower extremity in n = 42 cases.
Radiological follow-up with X-rays and MRIs was per-
formed regularly after surgery with intervals between 3
and 12months. Images were evaluated by a musculo-
skeletal radiologist subspecialized in orthopedic oncol-
ogy. Tumors were Campanacci grade III (n = 27) or
grade II (n = 24). Mean size of all tumors was 52.0 (±
47.8) cm3. Those tumors treated with hydrogen peroxide
were slightly larger, but this was not statistically signifi-
cant (Table 1; Fig. 2). Size and intraoperative blood loss
had a strong positive correlation (r = 0.501, p < 0.001).
Until the final follow-up, no metastases were found.
Histological evaluation included information on
angioinvasion and whether mitosis rate of the mono-
nuclear cell population was high (≥ 20 mitotic figures in
10 different high-power (400×) microscopic fields).
Angioinvasion was histologically verified in eight cases.
High mitosis rate was found in four cases, from those,
three had recurrences.
Clinical outcome was evaluated at the final follow-up
using a standardized questionnaire. Visual analog scale
ratings for patient satisfaction from 0 to 10 and limita-
tions of musculoskeletal function of the affected body
part were assessed. To compare limitations of musculo-
skeletal function of different body parts, score results
from the Oxford Knee Score, Oxford Hip Score, Foot
And Ankle Disability Index, and Quick Disabilities Of
Arm Shoulder And Hand Score were grouped into four
categories to rate disability (0 points = excellent function
without disability to 3 points = highest disability). Overall
clinical outcome was additionally evaluated by the Mus-
culoskeletal Tumor Society (MSTS) score (Table 1) in-
cluding functional parameter, emotional acceptance, and
pain [24].
Hydrogen peroxide use
Intralesional resection was done by vigorous curettage,
additional burring, and further cleaning of the cavity
with either physiologic salt solution or 3% hydrogen per-
oxide solution (988 mM, Hedinger, Stuttgart, Germany).
Concise information on whether hydrogen peroxide was
used or not was available for all cases. Before the tumor
cavity was filled, it was repetitively flushed with the solu-
tion and cancellous bone margins were mechanically
cleaned with a soaked compress. Mean application time
of the solution was 3 min.
In vitro analyses of hydrogen peroxide effects on GCT
cells
The influence of hydrogen peroxide on cell viability and
apoptosis induction was additionally quantified in vitro
using five primary GCT-derived stromal cell lines iso-
lated from fresh tumor tissue samples. Tumor tissue was
mechanically cut in small pieces and digested with 1.5
Fig. 1 Intralesional resection strategy with bone cement filling and additional osteosynthesis at the proximal tibia (a) and distal femur (b) with
preoperative images (on the left) and postoperative images (on the right)
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mg/ml collagenase B (Roche Diagnostics, Mannheim,
Germany) for 1 h at 37 °C in Dulbecco’s modified Eagle’s
medium (DMEM) (Sigma-Aldrich, Taufkirchen,
Germany) containing 4.5 g/l glucose, 10% fetal calf
serum (Biochrom, Berlin, Germany), and 100 U/ml peni-
cillin/streptomycin (Sigma-Aldrich). Cells were collected
by centrifugation, washed twice in PBS, and cultured in
DMEM. Twenty-four hours after plating, cells were
carefully treated with Trypsin/EDTA (Sigma-Aldrich)
leaving the giant cells attached in the culture flask. De-
tached neoplastic stromal cells were cultured for further
two passages. The obtained GCT stromal cells were used
for the investigation of hydrogen peroxide-induced ef-
fects. Cells were seeded in 24-well plates (50000 cells/
well) and cultured in DMEM with or without the
addition of hydrogen peroxide. The experiments were
adapted to the clinical scenario simulating intraoperative
flushing and cleaning with short time administration of
hydrogen peroxide. Therefore, DMEM was removed
from the well plates to flush the cells with 250 μl of
highly concentrated (988mM) ready to use 3% hydrogen
peroxide solution (Hedinger, Stuttgart, Germany) which
was equally used at surgeries. The hydrogen peroxide so-
lution was kept in the well plates for 3 s, 1 min, or 3 min
and then replaced by 1000 μl of DMEM to be further
incubated for 24 h in DMEM without hydrogen peroxide
to allow cell recovery.
Additional analysis of low-dose but long-time hydro-
gen peroxide treatment was performed with 0.5 mM, 1
mM, and 2mM hydrogen peroxide solution for 4 h.
For the analysis of cell viability and apoptosis induc-
tion, adherent and detached cells were collected and the
amount of viable cells was measured by propidium iod-
ide staining (2.5 μg/ml) (Invitrogen, Karlsruhe, Germany)
and subsequent flow cytometric quantification of posi-
tive cells as previously described [25]. Induction of apop-
tosis was quantified using the caspase-3 substrate
NucView-488 (Linaris GmbH, Dossenheim, Germany)
according to the manufacturer’s protocol with quantifi-
cation of apoptotic cells by flow cytometry.
Statistical analyses
Student’s t tests, analysis of variance (ANOVA) with post
hoc testing, and Mann-Whitney U tests were used to
compare differences depending on scale level and distri-
bution of the data. Recurrence rates were analyzed by
chi-square tests with likelihood ratios. Cumulative
recurrence-free survival was evaluated by Kaplan-Meier
analysis with log-rank testing to determine significant
differences. Multivariate Cox regression analysis was
Table 1 Treatment strategies with tumor characteristics and surgical and clinical parameter including the Musculoskeletal Tumor
Society (MSTS) score at final follow-up. Mean (± standard deviation) and median (range) are depicted
Lesion size at surgery in cm3 Number of recurrences Satisfaction (0–10) Disability (0–3) MSTS-score (0–30)
Total (n = 51) 52 (± 48) 21 9 (4–10) 0 (0–2) 28 (15–30)
Curettage with H2O2 (n = 27) 58 (± 50) 6 9 (4–10) 0 (0–2) 28 (16–30)
Curettage without H2O2 (n = 24) 46 (± 46) 15 9 (5–10) 0 (0–2) 27 (15–30)
Fig. 2 Box plots with preoperative tumor sizes in cubic centimeter. Size differences between cases treated with or without hydrogen peroxide
were not significant
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additionally performed to determine significant risk fac-
tors for tumor recurrence in association with multiple
factors. Statistical significance was assumed at a p value
≤ 0.05.
Results
Recurrences
From all 51 patients, we found later recurrences in 21
cases (41%). From 39 patients with first surgery at our
institution, 11 (28%) developed recurrences.
Univariate analysis revealed that recurrence rate was
not significantly different in tumors with angioinvasion,
soft tissue infiltration, higher Campanacci grade, or lar-
ger size. Filling with cancellous bone instead of bone ce-
ment increased recurrence rate (2.3-fold; likelihood ratio
5.1, p = 0.024; n = 51). Higher recurrence rates were also
observed if osteosynthesis was avoided (2.1-fold; likeli-
hood ratio 4.5, p = 0.034; n = 51). There was a trend to-
wards higher recurrence rate, if a pathological fracture
was evident before surgery (1.9-fold; likelihood ratio 2.1,
p = 0.149; n = 40) and if mitosis rate was high (2.0-fold;
likelihood ratio 2.1, p = 0.147; n = 49).
After hydrogen peroxide treatment, a strong and sta-
tistically significant impact on recurrence rate was ob-
served (3-fold lower recurrence rates; details are
depicted in Table 2 and Fig. 3).
Kaplan-Meier analysis was performed to estimate cu-
mulative recurrence-free survival. After additional osteo-
synthesis, cumulative recurrence-free survival was
significantly longer (at 2 years follow-up 0.75 (standard
error (SE) 0.09) versus 0.54 (SE 0.10); at 10 years
follow-up 0.67 (SE 0.11) versus 0.41 (SE 0.10); p = 0.05;
n = 51). If mitosis rate was high, cumulative
recurrence-free survival was significantly lower (at 2
years follow-up 0.25 (SE 0.22) versus 0.69 (SE 0.07); at
10 years follow-up: no case left versus 0.57 (SE 0.08); p =
0.019; n = 49) There was a trend for lower cumulative
recurrence-free survival in case of a pathological fracture
(at 2 years follow-up 0.38 (SE 0.17) versus 0.79 (SE 0.08);
at 10 years follow-up 0.38 (SE 0.17) versus 0.65 (SE
0.10); p = 0.077; n = 40) and if cancellous bone was used
instead of bone cement (at 2 years follow-up 0.50 (SE
0.20) versus 0.67 (SE 0.07); at 10 years follow-up 0.17
(SE 0.15) versus 0.60 (SE 0.08); p = 0.125; n = 51).
Kaplan-Meier analysis confirmed the strong positive
effect of hydrogen peroxide treatment (details are
depicted in Table 2 and Fig. 4).
Multivariate Cox regression analysis was performed to
further determine risk factors for tumor recurrence.
Hydrogen peroxide, bone cement, osteosynthesis, mitosis
rate, and pathological fracture were included. Significantly
higher risk for recurrence was confirmed for pathological
fracture (hazard ratio 3.7; 95% confidence interval (CI)
1.1–12.7; p = 0.04), high mitosis rate (hazard ratio 15.6;
95% CI 2.0–124.6; p = 0.01), and lack of hydrogen perox-
ide use (hazard ratio 6.0; 95% CI 1.3–28.3; p = 0.02).
Complications
Complication rate was 5 out of 51 and included one per-
ipheral venous thrombosis and four infections.
Clinical outcome
Hydrogen peroxide use versus no hydrogen peroxide use
did not significantly influence functional and emotional
outcome (compare Table 1).
In vitro analyses of hydrogen peroxide effects on GCT
cells
Short-time treatment with highly concentrated (988
mM) ready to use 3% hydrogen peroxide solution simu-
lated intraoperative treatment in the clinical situation
and quickly induced GCT cell death. Quantification of
Table 2 Recurrence rates with likelihood ratios and cumulative recurrence-free survival (RFS) rates at 2 years follow-up (2YFU), 5
years follow-up (5YFU), and 10 years follow-up (10YFU). Results are depicted for the whole collective and for cases with surgery at
own institution (in domo) and surgery elsewhere (ex domo). Statistically significant hydrogen peroxide effects were found for all
cases treated in domo and for the whole collective
n Recurrences
(recurrence rate)
Likelihood ratio of
recurrence (chi-square test)
2YFU-RFS
(standard error)
5YFU-RFS
(standard error)
10YFU-RFS
(standard error)
Log-rank test for
differences in RFS
Whole collective 51 21 (0.41) 0.69 (0.07) 0.54 (0.08) 0.54 (0.08)
Surgery in domo 39 11 (0.28) 11.9 (p = 0.001) 0.72 (0.08) 0.68 (0.08) 0.68 (0.08) p = 0.001
Surgery ex domo 12 10 (0.83) 0.42 (0.14) 0.17 (0.11) 0.17 (0.11)
With H2O2 (in
domo)
24 4 (0.17) 4.1 (p = 0.04) 0.86 (0.07) 0.79 (0.10) 0.79 (0.10) p = 0.02
Without H2O2 (in
domo)
15 7 (0.47) 0.48 (0.14) 0.48 (0.14) 0.48 (0.14)
With H2O2 (whole
collective)
27 6 (0.22) 8.8 (p = 0.004) 0.80 (0.08) 0.74 (0.09) 0.74 (0.09) p = 0.002
Without H2O2
(whole collective)
24 15 (0.63) 0.47 (0.11) 0.31 (0.10) 0.31 (0.10)
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caspase-3 activation, a key event within the apoptotic
cascade, verified the apoptotic nature of hydrogen
peroxide-induced cell death (Fig. 5a, b). Longer incuba-
tion time (4 h) with lower concentrations up to 0.5 mM
produced comparable results (Fig. 5c, d).
Discussion
The present series analyzed 51 advanced GCT cases
of the upper and lower extremities with a majority of
Campanacci grade III tumors. Contrary to other stud-
ies, which could not prove the additional effect of
hydrogen peroxide due to its heterogeneous use, we
for the first time could demonstrate that additional
adjuvant local hydrogen peroxide application after
curettage significantly reduced recurrence rate, in-
creased cumulative recurrence-free survival, and was
a significant risk factor in multivariate analysis.
Further in vitro analysis confirmed hydrogen
Fig. 3 Recurrence rates depending on whether hydrogen peroxide (H2O2) was used or not to clean the tumor cavity after curettage: Significantly
less recurrences were found after hydrogen peroxide treatment in the group of patients with surgery at our institution (a; n = 39) and in the
whole collective (b; n = 51)
Fig. 4 Kaplan-Meier analysis of cumulative recurrence-free survival (RFS). Survival curves are presented for the whole collective (a), for cases with
surgery at our institution (in domo) versus surgery elsewhere (ex domo) (b), and for treatment with or without hydrogen peroxide (H2O2) in
domo (c) and for the whole collective (d)
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peroxide-induced apoptotic cell death of GCT cells as
the underlying mechanism.
The literature describes heterogeneous use of local ad-
juvants to further clean the GCT cavity and kill poten-
tially remaining GCT cells before filling the defect with
bone cement or cancellous bone [5, 18, 22, 23]. Phenol
was mainly used but is abandoned due to serious sys-
temic toxicity and carcinogenic potential also for the
surgeon by inhalation. Multiple other adjuvants have
been described with, however, limited evidence due to
rare and heterogeneous usage. Besides the filling with
bone cement itself, local adjuvants can be divided into
thermal adjuvants (cryotherapy with liquid nitrogen;
cauterization) and toxic chemical substances such as al-
cohol, iodine, cyclophosphamide, phenol, and hydrogen
peroxide [5, 18, 22, 23]. Hydrogen peroxide is a cheap
and easily available adjunct which has been reported as
an alternative for phenol with proven in vitro effects
against GCT cells [26, 27], but its clinical value has not
been proven so far [5, 18, 22, 23]. The present study
documents statistically significant clinical effects of
hydrogen peroxide.
In the present study, we for the first time tried to
transfer the clinical intraoperative scenario of high-dose
short-time hydrogen peroxide application also to in vitro
analyses. Hydrogen peroxide is expected to kill poten-
tially remaining tumor cells in the tumor cavity after ag-
gressive curettage. These tumor cells are not
macroscopically visible but potentially scattered and at-
tached at the surface of the cavity. Hence, in vitro-isolated
GCT cells attached at the well plate might be an appropri-
ate target to test whether short-time application of highly
concentrated hydrogen peroxide solution can diminish vi-
able tumor cells in order to prevent later recurrence. After
initial short-time treatment of the attached cells with
hydrogen peroxide, cells were further incubated in DMEM
for 24 h without hydrogen peroxide to allow recovery.
This may resemble potential later tumor cell recovery
after hydrogen peroxide is diluted and removed from the
tumor cavity. Apart from general limitations based on the
artificial setup of in vitro studies, our data support detri-
mental hydrogen peroxide effects on GCT cells. We found
reduced cell viability and activated apoptotic pathways
both after high-dose short-time application and after lon-
ger incubation times with lower hydrogen peroxide
concentrations.
A further clinical advantage of hydrogen peroxide use
was improved cleaning of the cancellous bone margins
with better visibility compared to only cleaning with salt
solution. Hence, the surgeon may detect and resect re-
sidual tumor tissue more easily. As a result of the
present study, we generally recommend adjuvant local
use of easily available hydrogen peroxide to finally clean
the tumor cavity before filling the defect.
In agreement with most other studies [5, 16–19, 21],
our data also support that bone cement filling reduces
Fig. 5 Analysis of cell viability (a) and apoptosis induction (b) after high-dose short-time hydrogen peroxide treatment of n = 5 primary GCT-
derived stromal cell lines. Low-dose long-time treatment showed equal effects on cell viability (c) and apoptosis induction (d) (**p < 0.01)
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recurrence rate compared to cancellous bone filling,
which can be explained by heat destruction of potentially
remaining tumor cells during the exothermic
polymerization of polymethylmethacrylate. Another ad-
vantage is better radiological identification of potential
recurrences after bone cement filling [5]. The beneficial
effect of bone cement filling, however, was not con-
firmed by some other studies [15, 22, 23]. The majority
of our cases (45) had bone cement fillings, whereas only
six cases had cancellous bone fillings, which limits statis-
tical analysis. Statistical significance was only achieved
for the recurrence rate analyzed by chi-square tests. Dif-
ferences in cumulative recurrence-free survival did not
reach statistical significance.
Age, gender distribution, localizations, and recurrence
rates of our series are compatible with the literature.
Our overall high recurrence rate can be explained by the
majority of initially complicated and advanced cases in
our university institution, specialized in orthopedic on-
cology, as well as by the cases initially treated in other
surrounding hospitals and referred to us for further
follow-up due to their complexity. Another reason will
be our philosophy of avoiding extralesional wide resec-
tion with endoprosthetic reconstruction in the young
GCT population as much as possible and even in cases
with partial joint-line infiltration, due to long-time haz-
ards related to a tumor mega prosthesis. Some authors,
however, prefer wide resection in advanced Campanacci
grade III tumors [4] to minimize recurrences and avoid
multiple surgeries [5, 16]. Improvements of survival and
function of today’s tumor endoprostheses need further
long-time analysis.
Histologically, osteoclast-like multinuclear giant cells
and mononuclear neoplastic stroma cells influence
tumor activity [1, 28], but histological classification of
GCT was not reliable in predicting prognosis [5, 15, 29].
We also evaluated mitosis rate of the mononuclear cell
population and found that higher mitosis rate was asso-
ciated with significantly lower recurrence-free survival
and higher hazard ratio in multivariate analysis, which is
compatible with another report [21].
Molecular pathogenesis of GCT [30, 31] will influence
future therapeutic strategies. Adjuvant or neo-adjuvant
systemic treatment with denosumab, a RANKL inhibitor,
is increasingly used for cases where surgical resection
would cause inappropriate morbidity [32]. The present
study did not analyze denosumab treatment which might
improve outcome. From the authors’ experience, how-
ever, denosumab will be more appropriate for advanced
tumors in the pelvis and spine where complete surgical
tumor removal is not possible without mutilation. Even
higher postoperative recurrence rates in cases with
neo-adjuvant denosumab treatment have been reported
[33], which might be related to tissue remodeling with
less obvious tumor margins after denosumab treatment
making complete tumor removal more difficult for the
surgeon. These effects, however, are controversial as
beneficial reduction of tumor size was reported after
denosumab treatment [34] and randomized trials have
been initiated for further evaluation [8]. Optimal dur-
ation of denosumab treatment also remains unclear as
well as the risk for the induction of secondary osteosar-
comas [7, 8, 33, 34].
We observed higher recurrence rates and lower cumu-
lative recurrence-free survival in cases, where osteo-
synthesis was avoided. A possible explanation might be
more vigorous curettage and improved visibility in cases
with additional stabilization via osteosynthesis, as the
surgeon might have been less concerned about intra- or
postoperative fracture.
Important limitations of the present study have to be
acknowledged. Compared to some other studies, abso-
lute numbers of cases were low and depending on the
different parameter, data was not available for all cases.
Analysis was retrospectively performed and hydrogen
peroxide was heterogeneously used with potential bias.
As an additional cell-toxic adjunct will be more likely
used in complicated cases, the beneficial effect on recur-
rence rate will be, however, rather underestimated than
overestimated. For final evaluation, further studies are
needed with higher patient numbers, potentially pro-
spective study design and specific selection criteria for
hydrogen peroxide use. Nevertheless, the strength of the
present study is proof of principle for hydrogen peroxide
effectiveness by both in vitro cell culture studies and
clinical analyses with sufficient numbers of equally
treated patients with and without hydrogen peroxide
use.
Conclusion
For the first time, this study proves the clinical effective-
ness of adjuvant local hydrogen peroxide to clean the
cavity before defect filling. Hydrogen peroxide treatment
significantly reduced recurrence rate and increased cu-
mulative recurrence-free survival. Reduction of viable
GCT cells by induction of apoptosis analyzed in vitro
supports this.
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